| Product Code: ETC10765513 | Publication Date: Apr 2025 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 | |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 France Pemetrexed Market Overview |
3.1 France Country Macro Economic Indicators |
3.2 France Pemetrexed Market Revenues & Volume, 2021 & 2031F |
3.3 France Pemetrexed Market - Industry Life Cycle |
3.4 France Pemetrexed Market - Porter's Five Forces |
3.5 France Pemetrexed Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.6 France Pemetrexed Market Revenues & Volume Share, By Mechanism of Action, 2021 & 2031F |
3.7 France Pemetrexed Market Revenues & Volume Share, By Combination Therapy, 2021 & 2031F |
3.8 France Pemetrexed Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.9 France Pemetrexed Market Revenues & Volume Share, By Administration Route, 2021 & 2031F |
4 France Pemetrexed Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of lung cancer in France |
4.2.2 Growing adoption of targeted therapies in cancer treatment |
4.2.3 Favorable reimbursement policies for pemetrexed in the French healthcare system |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for drug approval in France |
4.3.2 High cost associated with pemetrexed treatment |
4.3.3 Competition from alternative treatment options in the oncology market |
5 France Pemetrexed Market Trends |
6 France Pemetrexed Market, By Types |
6.1 France Pemetrexed Market, By Indication |
6.1.1 Overview and Analysis |
6.1.2 France Pemetrexed Market Revenues & Volume, By Indication, 2021 - 2031F |
6.1.3 France Pemetrexed Market Revenues & Volume, By Non-Small Cell Lung Cancer, 2021 - 2031F |
6.1.4 France Pemetrexed Market Revenues & Volume, By Mesothelioma, 2021 - 2031F |
6.1.5 France Pemetrexed Market Revenues & Volume, By Breast Cancer, 2021 - 2031F |
6.1.6 France Pemetrexed Market Revenues & Volume, By Colorectal Cancer, 2021 - 2031F |
6.1.7 France Pemetrexed Market Revenues & Volume, By Pancreatic Cancer, 2021 - 2031F |
6.2 France Pemetrexed Market, By Mechanism of Action |
6.2.1 Overview and Analysis |
6.2.2 France Pemetrexed Market Revenues & Volume, By Antifolate, 2021 - 2031F |
6.2.3 France Pemetrexed Market Revenues & Volume, By DNA Synthesis Inhibition, 2021 - 2031F |
6.2.4 France Pemetrexed Market Revenues & Volume, By Enzyme Targeting, 2021 - 2031F |
6.2.5 France Pemetrexed Market Revenues & Volume, By Cell Growth Suppression, 2021 - 2031F |
6.2.6 France Pemetrexed Market Revenues & Volume, By Purine Synthesis Blockade, 2021 - 2031F |
6.3 France Pemetrexed Market, By Combination Therapy |
6.3.1 Overview and Analysis |
6.3.2 France Pemetrexed Market Revenues & Volume, By Platinum-Based Chemotherapy, 2021 - 2031F |
6.3.3 France Pemetrexed Market Revenues & Volume, By Immunotherapy, 2021 - 2031F |
6.3.4 France Pemetrexed Market Revenues & Volume, By Radiation Therapy, 2021 - 2031F |
6.3.5 France Pemetrexed Market Revenues & Volume, By Personalized Medicine, 2021 - 2031F |
6.3.6 France Pemetrexed Market Revenues & Volume, By Monoclonal Antibodies, 2021 - 2031F |
6.4 France Pemetrexed Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 France Pemetrexed Market Revenues & Volume, By Hospitals, 2021 - 2031F |
6.4.3 France Pemetrexed Market Revenues & Volume, By Oncology Clinics, 2021 - 2031F |
6.4.4 France Pemetrexed Market Revenues & Volume, By Specialty Clinics, 2021 - 2031F |
6.4.5 France Pemetrexed Market Revenues & Volume, By Research Institutes, 2021 - 2031F |
6.4.6 France Pemetrexed Market Revenues & Volume, By Pharmaceutical Companies, 2021 - 2031F |
6.5 France Pemetrexed Market, By Administration Route |
6.5.1 Overview and Analysis |
6.5.2 France Pemetrexed Market Revenues & Volume, By Intravenous, 2021 - 2031F |
6.5.3 France Pemetrexed Market Revenues & Volume, By Injection, 2021 - 2031F |
6.5.4 France Pemetrexed Market Revenues & Volume, By IV Infusion, 2021 - 2031F |
6.5.5 France Pemetrexed Market Revenues & Volume, By Cancer Treatment Centers, 2021 - 2031F |
6.5.6 France Pemetrexed Market Revenues & Volume, By Hospital Pharmacy, 2021 - 2031F |
7 France Pemetrexed Market Import-Export Trade Statistics |
7.1 France Pemetrexed Market Export to Major Countries |
7.2 France Pemetrexed Market Imports from Major Countries |
8 France Pemetrexed Market Key Performance Indicators |
8.1 Average number of new lung cancer cases diagnosed annually in France |
8.2 Adoption rate of pemetrexed in lung cancer treatment protocols |
8.3 Patient adherence rate to pemetrexed therapy |
8.4 Number of clinical trials evaluating pemetrexed for new indications |
8.5 Rate of adverse events reported in patients receiving pemetrexed |
9 France Pemetrexed Market - Opportunity Assessment |
9.1 France Pemetrexed Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.2 France Pemetrexed Market Opportunity Assessment, By Mechanism of Action, 2021 & 2031F |
9.3 France Pemetrexed Market Opportunity Assessment, By Combination Therapy, 2021 & 2031F |
9.4 France Pemetrexed Market Opportunity Assessment, By End User, 2021 & 2031F |
9.5 France Pemetrexed Market Opportunity Assessment, By Administration Route, 2021 & 2031F |
10 France Pemetrexed Market - Competitive Landscape |
10.1 France Pemetrexed Market Revenue Share, By Companies, 2024 |
10.2 France Pemetrexed Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here